1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Bionomics Posts Positive Data In PTSD With Struggling Anxiety Drug

 
• By Joseph Haas

After failing in a Phase II trial in social anxiety disorder, Bionomics thinks mid-stage data for BNC210 in post-traumatic stress disorder may now position the drug as a novel therapy for PTSD.

PTSD
Bionomics hopes to move into pivotal studies with latest PTSD data • Source: Shutterstock

Bionomics Limited has been all-in on its allosteric ion channel modulator BNC210 in neuropsychiatric indications for years and is bullish about moving forward now that the drug met the primary endpoint in a Phase IIb trial of 212 patients with post-traumatic stress disorder (PTSD). CEO Spyros Papapetropoulos told a same-day call that the company intends to discuss a regulatory pathway with the US Food and Drug Administration and thinks it could have a potential blockbuster on its hands.

Based in both Adelaide, Australia, and Cambridge, MA, Bionomics got an enthusiastic response from investors as its stock price soared on 28 September on the positive data, finishing up 244% to $3.37 per share. This is a welcome turnaround for the company after its stock price fell following an unsuccessful Phase II readout for BNC210, a negative modulator of the alpha7 nicotinic acetylcholine receptor (a7 nAChR), in social anxiety disorder (SAD) last December

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

In Brief: Strong OS Results For Immutep’s Eftilagimod/Keytruda Combo In Head And Neck Cancer

 
• By Sushmita Panda

Australian firm's combo of eftilagimod and Keytruda shows 17.6-month median overall survival in first-line HNSCC patients with low PD-L1, raising hopes for potential accelerated approval.

In Brief: Positive New Data For Aptose’s Triplet Therapy In 1L AML

 
• By Sushmita Panda

Aptose’s tuspetinib triplet shows early mutation-agnostic promise in new data from Phase I/II program for frontline acute myeloid leukemia.

Chinese Firms Build Obesity Clinical Pipeline But Face Wider Hurdles

 
• By Xu Hu

Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.

Aldeyra Plans To File Reproxalap Again With New Dry Eye Symptom Data

 
• By Joseph Haas

The biotech hopes a third time will be the charm after two FDA complete responses, with plans to position its eye drop as offering quicker onset of action.

More from R&D

Lilly And Alchemab Tap Into Resilient Individuals To Develop ALS Drug

 
• By Andrew McConaghie

The pharma company is helping to validate the biotech’s model by developing a novel amyotrophic lateral sclerosis candidate, based on its novel approach that ‘turns drug discovery on its head’.

Pipeline Watch: Thirteen Approvals And Ten Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Accelerated Approval May Be Out Of Reach For PTC’s Huntington’s Drug

 
• By Joseph Haas

PTC said its updated Phase II data for PTC 518 met the primary endpoint of Huntingtin’s protein reduction, but analysts said there isn’t clear correlation with clinical benefit.